Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Benedetti

Showing results (221-230 of 265) with videos related to

Pageof 27
Sort By:
Haematologica|March 1, 1991
High dose chemotherapy with cisplatin, VP16 and carboplatin with stem cell support in patients with advanced ovarian cancerL Pierelli, G Menichella, M L Foddai, et al.
British Journal of Haematology|November 1, 1991
Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancerG Menichella, L Pierelli, M L Foddai, et al.
Gynecologic Oncology|April 1, 1992
Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II)G Scambia, F O Ranelletti, P Benedetti Panici, et al.
Cancer Treatment Reviews|October 14, 2017
Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should knowF De Felice, C Marchetti, S M Boccia, et al.
Critical Reviews in Oncology/Hematology|April 14, 2018
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trialsC Marchetti, F De Felice, A Di Pinto, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancerP Benedetti-Panici, S Greggi, G Scambia, et al.
International Journal of Cancer|September 4, 1995
Methyl-p-hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: correlation with biological and clinico-pathological parametersF O Ranelletti, G Scambia, P Benedetti Panici, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sitesG Scambia, F O Ranelletti, P Benedetti Panici, et al.
International Journal of Cancer|January 2, 1994
Significance of epidermal growth factor receptor expression in primary human endometrial cancerG Scambia, P Benedetti Panici, G Ferrandina, et al.
Leukemia Research|January 1, 1992
The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growthL Teofili, L Pierelli, M S Iovino, et al.
Pageof 27

Showing results (221-230 of 265) with videos related to

Sort By:
Pageof 27
Haematologica|March 1, 1991
High dose chemotherapy with cisplatin, VP16 and carboplatin with stem cell support in patients with advanced ovarian cancerL Pierelli, G Menichella, M L Foddai, et al.
British Journal of Haematology|November 1, 1991
Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancerG Menichella, L Pierelli, M L Foddai, et al.
Gynecologic Oncology|April 1, 1992
Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II)G Scambia, F O Ranelletti, P Benedetti Panici, et al.
Cancer Treatment Reviews|October 14, 2017
Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should knowF De Felice, C Marchetti, S M Boccia, et al.
Critical Reviews in Oncology/Hematology|April 14, 2018
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trialsC Marchetti, F De Felice, A Di Pinto, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancerP Benedetti-Panici, S Greggi, G Scambia, et al.
International Journal of Cancer|September 4, 1995
Methyl-p-hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: correlation with biological and clinico-pathological parametersF O Ranelletti, G Scambia, P Benedetti Panici, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sitesG Scambia, F O Ranelletti, P Benedetti Panici, et al.
International Journal of Cancer|January 2, 1994
Significance of epidermal growth factor receptor expression in primary human endometrial cancerG Scambia, P Benedetti Panici, G Ferrandina, et al.
Leukemia Research|January 1, 1992
The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growthL Teofili, L Pierelli, M S Iovino, et al.
Pageof 27